Shareholders of the embattled drugmaker Mylan voted to re-elect its board members at a meeting Thursday morning, despite pressure to oust select executives amid widespread backlash for the skyrocketing price of EpiPens.
The American Medical Association last week left no room for doubt about its stance on legislative proposals to cap Medicaid funding: That would be "disastrous," AMA board member Dr. Carl Sirio said.
Pfizer subsidiary Hospira issued a nationwide recall of the vials used to inject sodium bicarbonate due to sterility concerns. The recall exacerbates the current shortage of the potentially lifesaving drug.
Nevada Gov. Brian Sandoval signed into law Thursday the nation's strictest requirements for pharmaceutical companies to reveal how they set certain prescription drug prices.
Making actual generic drug acquisition costs available to third-party payers would empower health plans to negotiate lower rates and essentially level the playing field in a pharmaceutical supply chain that's shrouded in secrecy, according to a new paper.
Blink Health and Express Scripts partnered with Eli Lilly to provide up to a 40% discount on the drugmaker's insulin. An Express Scripts spokesman said Blink ended the contract because it did not want an exclusive relationship with the PBM, a violation of their agreement.
PricewaterhouseCoopers Health Research Institute projected that medical costs in 2018 will increase by 6.5% from 2017, but that still outpaces general inflation by two to three times and is unsustainable.
Citing "exorbitant" expenses in addressing the mounting opioid crisis, Nassau County on Monday joined a growing number of local governments suing major pharmaceutical companies, accusing them of contributing to the explosive growth in opioid addiction and overdose deaths.
A unanimous Supreme Court is speeding up the time for generic biotech drugs to become available to the public in a ruling that means a loss of billions in sales to the makers of original versions.
Several major pharmacy benefit managers and drug distributors have sued the Cherokee Nation over its attempt to make them pay for the widespread distribution of opioids that has allegedly contributed to the opioid addiction that has beset its tribal members.
The American Medical Association will debate drug price control measures as many physicians report hearing from their patients that they can't afford their medications.
The FDA's request marks one of the first times the agency has tried to get an opioid pain medication off the market because of the public health consequences of abuse.